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Abstract—With the large number of Veterans experiencing 
posttraumatic stress disorder (PTSD) and chronic pain, the pur-
pose of this article is to review the prevalence of PTSD and 
chronic pain, the theoretical models that explain the mainte-
nance of both conditions, and the challenges faced by providers 
and families who care for these patients. The Department of 
Veterans Affairs (VA)/Department of Defense (DOD) VA/DOD 
Clinical Practice Guideline for Management of Post-Traumatic 
Stress with special attention to chronic pain is presented. Lim-
ited scientific evidence supports specific care and treatment of 
PTSD and chronic pain, and this challenges providers to investi-
gate and research potential treatment options. Integrated care 
models designed for working with these patients are reviewed, 
including a focus on the techniques and strategies to address not 
only PTSD and chronic pain, but other conditions, including 
substance dependence and depression. A specific focus on 
headaches, back pain, and neuropathic pain follows, including 
treatment recommendations such as pharmacological, psycho-
therapeutic, and complementary approaches, given the high 
rates of these pain complaints for Veterans in PTSD clinical pro-
grams. Integrated care is presented as a viable solution and 
approach that challenges clinicians and researchers to develop 
innovative, scientifically based therapeutics and treatments to 
enhance the recovery and quality of life for Veterans with PTSD 
and chronic pain.
Key words: behavioral activation, blast injury, buprenorphine, 
chronic pain, comorbid illness, integrated care, opioid depend-
ence, posttraumatic stress disorder, rehabilitation, Veteran.
INTRODUCTION
As of November 17, 2011, 6,320 U.S. servicemem-
bers have been killed in Afghanistan (Operation Endur-
ing Freedom [OEF]) and Iraq (Operation Iraqi Freedom 
[OIF]) [1]. An estimated 50,000 to 100,000 servicemem-
bers have experienced nonmortal wounds and injuries 
during military deployments in OIF/OEF. The number of 
those injured is staggering, with an unprecedented num-
ber of injured U.S. servicemembers returning home com-
pared with previous historical military actions.
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OIF/OEF have resulted in the highest wounded to 
fatality ratio compared with past conflicts involving U.S. 
servicemembers. The wounded to fatality ratio for our 
current military actions is 16 servicemembers wounded 
per every fatality. During World War I and World War II, 
there were two servicemembers wounded per every fatal-
ity. For the conflicts in Korea and Vietnam, the wounded 
to fatality ratio was close to three wounded per every 
fatality [2]. Our nation’s wars prior to OIF/OEF resulted 
in a far greater loss of American lives, with not only 
fewer servicemembers surviving war injuries, but also a 
greater number being called to serve in combat.
With a significantly greater number of servicemembers 
surviving devastating combat injuries today, it is clear that 
much credit is due to the incredible advances in military 
medicine. More servicemembers are surviving major com-
bat injuries with the resulting medical, psychological, and 
social costs to servicemembers, their families, and the 
Department of Defense (DOD) and Department of Veterans 
Affairs (VA) medical systems to provide care for those with 
combat-related injuries. This has resulted in the emergence 
of multimodal pain management with the identification of 
proactive, not reactive, pain management to contribute to 
early rehabilitation and recovery [3]. These Veterans and 
servicemembers require complex medical care and our 
medical systems are constantly challenged to address their 
physical as well as psychological injuries, such as posttrau-
matic stress disorder (PTSD), as Veterans take steps for-
ward in their lives following military discharge.
In response to the comorbid presentations of both 
PTSD and chronic pain, the VA/DOD Clinical Practice 
Guideline for Management of Post-Traumatic Stress was 
revised in 2010 with a special section devoted to the 
management and treatment of pain in patients who have 
PTSD. This article will highlight the clinical practice 
guideline with the primary purpose of helping clinicians 
gain a deeper understanding of these conditions as we 
continue to or begin to develop models of care to best 
meet the treatment needs of these patients. We must work 
in collaboration to integrate the care provided in our 
medical centers for all Veterans with both PTSD and 
chronic pain.
METHODS
A search of Medline (Medical Literature Analysis and 
Retrieval System Online), CINAHL (Cumulative Index to 
Nursing and Allied Health Literature), AMED (Allied and 
Complementary Medicine Database), and PsycINFO (Psy-
chological Information Database) was performed. No start 
date limit on the search criteria of the databases was set, 
but the end date was the first week of August 2011.
The search was performed using the following com-
binations of terms:
  • “PTSD and Chronic Pain” within title and abstract.
  • “Posttraumatic Stress Disorder and Chronic Pain” within 
title and abstract.
  • “(Posttraumatic Stress Disorder or Chronic Pain) AND 
therapy” within title and abstract.
  • “(Posttraumatic Stress Disorder or Chronic Pain) AND 
medications” within title and abstract.
  • “(Posttraumatic Stress Disorder or Chronic Pain) AND 
depression.”
  • “(PTSD or Chronic Pain)) and Substance Abuse” within 
title and abstract.
  • “Chronic Pain and Opioids” within title and abstract.
    • “Chronic Pain and Buprenorphine” within title and 
abstract.
  • “Chronic Pain and Headaches” within title and abstract.
  • “Chronic Pain and Neuropathic Pain” within title and 
abstract.
  • “Chronic Pain and Back Pain” within title and abstract.
  • “PTSD and Headaches” within title and abstract.
  • “PTSD and Neuropathic Pain” within title and abstract.
  • “PTSD and Back Pain” within title and abstract.
  • “Integrated Care” within title and abstract.
The reviewer independently read the titles and abstracts of 
the studies found in the search and compiled them for the 
purpose of this comprehensive review article. Study partici-
pants were adult patients with PTSD and/or chronic pain. 
There are limited randomized controlled trials on both 
PTSD and chronic pain, so this could not be a primary 
inclusion criteria. All articles were published in a peer-
reviewed journal.
RESULTS
Chronic Pain
Returning servicemembers experience various forms 
of chronic pain, including, but not limited to, soft tissue 
injuries and musculoskeletal pain; neuropathic pain; pain 
related to severe burn injuries and/or grafts; pain caused 
by imbedded shrapnel or metal or bone fragments; pain 755
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related to amputation and/or phantom limb pain; pain 
secondary to surgeries; and pain related to compression 
fractures or injuries from falls, jumps, or other types of 
impact. Many of the aforementioned pain conditions are 
a direct result of military service and injuries incurred 
during service. We must also be aware of the high fre-
quency of chronic daily headaches, tension headaches, 
migraine headaches, chronic lower-back pain, fibromyal-
gia, and other pain disorders that may not necessarily be 
a direct effect of military service or injury during service.
It is well known that chronic pain can lead to the 
development of intense psychological distress, suffering, 
and functional disability. Pain is described as an unpleas-
ant sensory and emotional experience that is associated 
with actual or potential tissue damage [4]. Typically, pain 
is a temporary experience; for some, pain may persist to 
the point that it contributes to affective distress, increased 
use of medical services, and workplace absenteeism, with 
resultant impairment in social and occupational function-
ing [5–7]. Pain is the most common complaint made by 
patients to their primary care providers, with an estimated 
$75 to $100 billion a year in the United States in lost pro-
ductivity and healthcare costs; the burden of chronic pain 
on the individual, families, and medical system of care is 
significant [8]. It is also well know that there is a high pro-
pensity for the development of long-term mental health 
and substance abuse disorders in those suffering from 
chronic pain. Chronic pain has been recognized as the 
leading cause of short- and long-term disability among 
military personnel, thereby prompting the DOD and VA to 
look at the clinical programs and services currently avail-
able and to promote further research and attention to 
chronic pain and its related comorbid disorders.
PTSD
The prevalence rates of PTSD in the general popula-
tion are found to be 6 percent in males and 12 percent in 
females [9]. Most people are resilient and can absorb the 
effect of a traumatic experience and resume their normal 
lives. Estimates reveal that exposure to traumatic events 
for those living in the United States are thought to be close 
to 70 percent [10–11]. Although most people are resilient, 
a sizeable number cannot absorb the effect of traumatic 
events and develop PTSD. At-risk groups include those 
involved in motor vehicle accidents, sexual assault, or 
military combat, with the rates of PTSD found to be sub-
stantially higher than the general civilian population. 
Dohrenwend et al. reported that 18.7 percent of Vietnam 
war Veterans had developed war-related PTSD during 
their lifetimes and 9.1 percent continued to experience 
PTSD 11 to 12 years after the war following a review of 
military records to construct a new combat exposure 
measure [12]. Richardson et al. examined prevalence esti-
mates of combat-related PTSD in U.S. military Veterans 
since the Vietnam war and found that 2 to 17 percent of 
Vietnam war Veterans had PTSD. Studies from OIF/OEF 
suggest that combat-related PTSD affects between 4 and 
17 percent of U.S. OIF Veterans [13]. The rates are 
believed to be closer to 50 percent with those Veterans 
who have served multiple deployments and will increase 
with the number of firefights engaged.
Intersection of PTSD and Pain
Complaints of pain are commonly reported in patients 
who have PTSD, regardless of the traumatic experience 
such as military combat, motor vehicle accident, or sexual 
assault. The reporting of pain symptoms with functional 
impairment is also independent of the military service 
period and is seen across the board for World War II, 
Korean war, Vietnam war, Persian Gulf war (PGW), and 
OIF/OEF Veterans [14–19]. Among adult survivors of 
physical, psychological, or sexual abuse, the most com-
mon types of chronic pain include pelvic pain, lower-back 
pain, facial pain, and bladder pain, along with a high preva-
lence of fibromyalgia [20–21]. In OIF/OEF over the past 
10 years, there has been increased interest in the relation-
ship between PTSD and chronic pain.
The Veterans Health Administration (VHA) Office of 
Public Health and Environmental Hazards reported in 
April 2011 that mental disorders occur at a frequency of 
50.7 percent for servicemembers returning from OIF/
OEF and that diseases of the musculoskeletal system 
occur at a frequency of 54.7 percent for those who have 
served in OEF and/or OIF [22]. Patients with persistent 
chronic pain associated with musculoskeletal injury or 
serious burn injuries frequently experience PTSD. The 
National Co-Morbidity Study found that patients with 
musculoskeletal pain are four times more likely to 
develop PTSD than those without musculoskeletal pain 
[9]. Head, neck, back, shoulder, and knee pain have been 
found to be the most common pain complaints for those 
who served during OIF/OEF [19].
Clinical and military registries have found pain 
symptoms and diagnoses to be among the most prevalent 
conditions reported for PGW Veterans since the cease-fire 
in 1991. DOD and VA PGW registries’ most frequently 756
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diagnosed medical conditions include musculoskeletal
pain at rates of 25 percent and connective tissue diseases 
at rates of 36 percent. A survey of 15,000 PGW Veterans 
found prevalence rates for headaches at 54 percent, joint 
pain at 45 percent, back pain at 44 percent, muscle pain at 
33 percent, and abdominal pain at 23 percent [23–25]. 
Combat Veterans have high rates of pain that also occur 
with comorbid disorders and are often associated with 
worse outcomes.
The rates of PTSD when pain is secondary to a motor 
vehicle accident range from 30 to 50 percent. Burn 
patients have high rates of PTSD that are close to 45 per-
cent. For those servicemembers currently deployed to 
OIF/OEF, exposure to improvised explosive devices, 
other blast mechanisms, and refueling accidents has been 
found to increase the rates of burn injuries that are then 
associated with later development of PTSD. Those with 
PTSD report more intense pain and affective distress, 
higher levels of life interference, and greater disability 
than pain patients without PTSD. It has also been noted 
that re-experiencing symptoms were also associated with 
increased pain level and pain-related disability [26–27]. 
For those individuals who have both PTSD and chronic 
pain, the presence of both disorders may increase the 
severity and individual suffering from either condition.
PTSD symptoms are also associated with greater 
reporting of physical health problems and symptoms. Of 
outpatient Vietnam war combat Veterans with PTSD, 
80 percent satisfied the criteria for chronic pain in one or 
more sites, with 77 percent reporting back pain. It was 
also found that increased re-experiencing symptoms were 
connected to an increased pain level and associated pain-
related disability [16]. Pain threshold and tolerance are 
affected by elevations in anxiety, such as that seen in 
individuals with PTSD. PTSD may reduce pain threshold 
and pain tolerance, thereby influencing emotional dis-
tress and increasing perceived disability levels.
Similar to the presentation of pain symptoms for Viet-
nam war combat Veterans with PTSD, it is also known 
that a substantial number of returning Veterans experience 
ongoing or new pain postdeployment. According to a 
recent study, OIF Veterans report pain conditions more 
frequently than other medical conditions, with 47 percent 
reporting some level of current pain. Of OIF Veterans, 
28 percent reported pain scores that were associated with 
functional interference and scores that were at the thresh-
old for intervention, with a pain score 4 on the numeric 
pain scale [28].
Theoretical Models of PTSD and Chronic Pain
Four theoretical models have been proposed to out-
line the connections between PTSD and chronic pain. 
These include the Shared Vulnerability model, the Mutual 
Maintenance model, the Fear-Avoidance model, and the 
Triple Vulnerability model. These models have yet to be 
formally tested; however, the models can provide more 
understanding of the symptom overlap between both
PTSD and chronic pain, which can prove to be useful on a 
clinical basis.
The Shared Vulnerability model outlines anxiety sen-
sitivity as a predisposing factor contributing to the devel-
opment of both conditions. Those with increased levels of 
anxiety sensitivity are more likely to become fearful in 
response to bodily sensations such as pain or following 
exposure to a traumatic stressor. It is proposed that anxiety 
sensitivity can be a factor that makes an individual vulner-
able to the development and maintenance of chronic pain 
and PTSD by driving avoidance behaviors associated with 
both conditions [29].
The Mutual Maintenance model describes seven spe-
cific components that play a role in the chronic mainte-
nance of PTSD and pain:
  1. Anxiety sensitivity with the tendency to view events 
or outcomes as potentially tragic.
  2. Physical pain as a reminder of the traumatic event.
    3. Attentional biases that increase awareness and vigi-
lance to perceived threatening or painful circumstances.
  4. Avoidance as a means to cope with disturbing thoughts 
and pain.
  5. Elements of fatigue and lethargy that drive depres-
sion associated with both conditions.
  6. General fears and worries common to both disorders.
  7. Overwhelming cognitive demands of both disorders 
that limit the use of learned coping techniques [30].
It is believed that these components primarily drive the 
maintenance and chronic nature of both illnesses and ulti-
mately interfere with individuals engaging in treatment.
The Fear-Avoidance model describes the role of 
avoidance in the maintenance and development of both 
PTSD and chronic pain. Individuals with PTSD are driven 
by the fear of experiencing overwhelming thoughts or 
feelings of past traumatic events and avoid reminders 
associated with the traumatic event at all costs. This fear 
and avoidance contributes to the chronic nature of the ill-
ness through the prevention of processing of the traumatic 
event. Without processing the traumatic event, individuals 757
GIBSON. PTSD and chronic pain
with PTSD are propelled to isolate and avoid potentially 
traumatic reminders [31–32].
Finally, the Triple Vulnerability model of anxiety and 
PTSD outlines a set of vulnerabilities that must be 
present to develop an anxiety disorder, such as a general-
ized biological vulnerability, a generalized psychological 
vulnerability, and a specific psychological vulnerability 
where one focuses anxiety on specific situations. With 
PTSD, emotional reactions to events emerge in an unpre-
dictable and uncontrollable way. With chronic pain, when 
one perceives her or her pain as uncontrollable, this 
drives an individual’s sense of low self-efficacy and 
depression. At this point, individuals will avoid situations 
in which pain may occur, as also seen in PTSD. The 
alarm of a trauma reminder or pain reminder, along with 
the sense of uncontrollability, is believed to foreshadow 
the establishment of both illnesses [33–34].
With further examination and translation to clinical 
work with former combat Veterans, it is my opinion that 
the Mutual Maintenance model appears to be the theoreti-
cal model that is commonly seen in Veterans with both 
PTSD and chronic pain. Both illnesses seem to drive the 
challenges that many Veterans and their loved ones face as 
they struggle to re-engage in their lives outside of their 
combat traumas and military experience. Many Veterans 
with both disorders will say that, prior to the development 
of PTSD and chronic pain, they were very active with their 
families and friends. For many, this involved playing 
sports, going to the park with their kids, exercising on a 
regular basis, and attending sporting events with their 
friends. With both disorders, Veterans share a profound 
struggle with resistance to engaging in physical activity 
because of the possibility of exacerbating their chronic 
pain and avoidance of going to the park or other public 
places because of their anxiety and emotional distress 
when in a crowded place. This leads to a cycle of guilt, 
shame, and regret, in that many Veterans will say they 
wish they could be at the park or the sporting event or with 
their families. They also say that they miss the physical 
aspects of their lives prior to combat, but with their avoid-
ance symptoms, they find an enduring sense of safety and 
relief when they remain at home. This is the cycle of 
PTSD and pain that is maintained and challenges us as cli-
nicians when we provide treatment for our patients.
Avoidance is believed to prevent habituation to 
trauma-related reminders, lead to temporary reductions in 
anxiety, and therefore, increase the prolonged maintenance 
of anxiety. Among physically injured trauma survivors, 
there is evidence that avoidance may also be maintained 
by pain as noted in the earlier models of chronic pain and 
PTSD [30,35–36]. Avoidance in physically injured trauma 
survivors is also believed to be maintained by physical dis-
ability [37] and physical disfigurement [38]. Avoidance 
can be demonstrated as restriction in activities and possible 
pain medication overuse and is then maintained by fear, 
pain, and ruminations about the past.
When examining these factors, we can see that there 
are different avenues to approaching care with Veterans. 
A Veteran presenting for mental health treatment may 
only be ready to accept treatment for chronic pain because 
it may be too emotionally overwhelming for the patient to 
even consider engaging in trauma-focused psychotherapy 
to address PTSD. With some relief of physical pain and a 
deeper understanding of how PTSD can drive chronic 
pain, patients can then be better prepared to take the next 
step in PTSD treatment. The development of trust will 
naturally occur as we meet our patients, and it can then 
become possible for them to begin trauma-focused 
therapy for PTSD. On the other hand, some patients may 
present with PTSD symptoms that are the primary focus 
of attention and will say that they can live with their 
chronic pain. It is not uncommon for a clinician to hear 
that physical pain is something that Veterans learned to 
tolerate during military training so that they would be able 
to endure sleep deprivation, terrible weather conditions, 
and extreme physical exhaustion in order to accomplish 
missions during combat action. They now identify that the 
physical pain is limiting at times; however, they feel far 
more distressed by their PTSD symptoms. These patients 
may be ready to engage in trauma-focused therapy in 
order to find some emotional relief from disabling com-
bat-related thoughts and images. For these patients, it has 
been my experience that, with completion of trauma-
focused PTSD therapy, their ability to tolerate and live 
with their chronic pain symptoms also improves to a sig-
nificant degree.
Blast Injuries
For OIF/OEF Veterans, blast injuries have resulted in 
a devastating, complex array of injuries. The combina-
tion of PTSD symptoms, chronic pain, and postconcus-
sion syndrome has been found to be unique to OIF/OEF 
Veterans [39–41]. This constellation of comorbid ill-
nesses is more common in patients with blast injury and 
appears to be more challenging to address than each con-
dition alone. Given the effect of these blasts, not only the 758
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risk of the inherent physical injuries exists, but also 
numerous mechanisms for potential exposure to the psy-
chological and emotional effect of these traumas can then 
result in the development of PTSD [42]. Review of the 
article on PTSD and traumatic brain injury by Capehart 
and Bass (p. 789) will provide more detailed information 
about this specific topic.
Previous studies have shown that severely injured 
patients who require extended days of hospital care 
appear to be more likely to develop PTSD [43–44] and 
benefit less from traditional cognitive behavioral therapy 
(CBT) than patients who are less injured [45].
Servicemembers injured by blasts exhibit a broader 
spectrum of physical injuries that result in higher levels 
of hospital admission and discharge following return 
from combat action. These Veterans are also more likely 
to be prescribed opiate analgesics for the management of 
their pain symptoms. They also exhibit reduced improve-
ment in pain intensity posttreatment than those Veterans 
who were not exposed to blasts during combat action. 
Note that there were much higher rates of PTSD and 
other psychiatric diagnoses in those injured by blasts than 
in those injured by other means, such as combat injuries 
other than blast and noncombat and nonblast injuries 
[46]. Combat Veterans with chronic pain and PTSD are 
hyperaware of bodily sensations, resulting in greater 
severity scores of chronic pain.
Comorbid Disorders in PTSD and Chronic Pain
Co-occurring disorders for individuals with both 
PTSD and chronic pain are also prevalent and can lead to 
greater functional impairment and disability. Depression 
occurs in nearly half of all of those who are receiving 
treatment and services for chronic pain. Notably, pain is 
also present in up to two-thirds of all of those who are 
treated for depression [47]. Depression is common with 
both PTSD and chronic pain. Fatigue and reduced activity 
levels exacerbate and maintain both PTSD and chronic 
pain symptoms. Among chronic pain patients, depression 
prevalence rates were estimated at 30 to 54 percent, much 
higher than in the general population. Depression may 
result as a consequence of pain, may precede the pain, 
and may be related to the maintenance of pain. A biopsy-
chosocial approach to pain will best recognize what is 
likely a reciprocal relationship between emotional distur-
bances and pain [48–49].
Substance use disorders are also found at relatively 
high rates in those with chronic pain. In a population of 
patients treated for opiate addiction who are maintained on 
methadone, the rates of chronic pain are reported at 
approximately 37 to 60 percent [50]. Alcohol and other 
substances are also commonly used to cope with the men-
tal health effect of military deployment, including the self-
management of depression, anxiety, PTSD, and chronic 
pain [51–52]. It is also found that substance use disorders 
are underrecognized in those returning from deployment. 
Self-medication with alcohol and drugs is a common reac-
tion among people with PTSD and chronic pain; the conse-
quences can be hazardous, especially with the combination 
of alcohol, prescription pain medications, and centrally 
acting anxiolytics. The cycle of avoidance in both PTSD 
and chronic pain is fueled by overuse or misuse of pre-
scription pain medications and this concerning issue will 
be discussed later in this article. The VA has responded to 
the underrecognition of substance use disorders in all Vet-
erans by aggressively promoting screening, education, pre-
vention, and treatment of substance use disorders for all 
Veterans [53].
Steps to Integrated Care Approach
Given the high prevalence of comorbid illnesses in 
Veterans with both PTSD and chronic pain, we are tasked 
to look closely at integrated care models. Integrated treat-
ments for patients with PTSD and chronic pain should, 
most importantly, focus on the unique experiences of the 
individual Veteran and the contributions of his or her physi-
cal, psychological, emotional, and spiritual makeup. It is
critical to treat the whole person in order to gain a further 
understanding of the effect of trauma on the development 
and maintenance of both chronic pain and PTSD [54–55]. 
For our patients to achieve recovery and be able to move 
forward in their lives as they heal from both emotional and 
physical pain, we as mental health providers must help 
them become keenly aware of how their thoughts affect all 
aspects of their lives. Through the development of aware-
ness with education about the intersection of PTSD and 
chronic pain, our patients can become more mindful and 
tuned in to how they are emotionally affected by their 
external environmental triggers and by their internal emo-
tional triggers [56]. By working closely with patients to 
raise their awareness of internal and external cues that 
drive physical pain or trigger PTSD symptoms, such as 
nightmares or intrusive thoughts, we can effectively help 
our patients acquire the necessary skills to allow more 
positive coping.759
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Prior to 2010, in the absence of treatment guidelines for 
PTSD and chronic pain, Wald et al. suggested modifying 
conventional protocols with pain treatment, including psy-
choeducation, relaxation strategies, and cognitive restruc-
turing, delivered before PTSD treatment [57]. The general 
approach was to focus on the treatment of one illness and 
then approach the second illness with the hopes that this 
serial care plan would be able to provide the best clinical 
outcomes for the patient.
Research has also suggested that biofeedback (BF) is 
an effective pain treatment, but insufficient as a PTSD 
treatment [58–59]. There are no findings on the efficacy of 
treatment protocols addressing comorbidity in PTSD
patients; however, there is information to be learned from 
research studies with traumatized refugees. Comorbid
PTSD and chronic pain have been reported in 76 percent 
of traumatized refugees seeking treatment [60]. Factors 
complicating treatment for this population include culture-
specific symptom presentations, language barriers, and
differences between patients’ and therapists’ expectations 
about treatment [61]. These factors can also be translated 
to the provision of care for servicemembers and Veterans. 
Veterans strongly and preferentially identify with being 
part of a separate culture, and they often may have differ-
ent expectations about treatment than civilian providers. 
BF was selected as a treatment option for the refugee 
population because CBT for both PTSD and chronic pain 
is heavily language-based and can be a barrier to the treat-
ment of refugees. BF is relatively independent of cultural 
variations and the immediate physiological feedback can 
prove to be an advantage for the specific population of 
Veterans that experiences comorbid PTSD and pain.
Dahl et al. found that acceptance of the intervention 
was high and dropouts were unrelated to treatment [60]. 
The physiological orientation of the intervention allows 
validation of the patients’ illness as somatic and enables 
them to experience the ability to control their symptoms, 
thereby directly confronting stigma associated with seek-
ing treatment for “something in one’s head.” Regaining a 
sense of mastery over their symptoms can help to modify 
the sense of uncontrollability experienced by those with 
both PTSD and chronic pain as described in the Triple 
Vulnerability model of PTSD and chronic pain. As
expected, there was no reduction in PTSD symptoms; how-
ever, general psychopathology was lower at the 3-month 
follow-up. This suggests that BF may be an adjunctive 
treatment for PTSD through induction of relaxation and 
reduction of sympathetic arousal, but it is not a primary 
treatment. The implementation of BF in an integrated care 
model to treat PTSD and chronic pain may prove to be a 
solid starting point in treatment planning for patients.
VA/DOD CLINICAL PRACTICE GUIDELINE FOR 
MANAGEMENT OF POST-TRAUMATIC STRESS
Understanding the development and maintenance of 
PTSD and chronic pain along with the formulation of this 
complex relationship is often overlooked in clinical prac-
tice by primary care providers, mental health providers, 
and chronic pain providers. Given that rates of pain for 
Veterans with PTSD are high and that comorbid disorders 
are common and often lead to worse outcomes with a pro-
longed and severe course of illness, the VA/DOD clinical 
practice guideline for the management of PTSD was 
revised in 2010 with a special section devoted to the man-
agement of pain [62]. The interaction of these two disor-
ders challenges all of us as clinicians, working in a variety 
of different clinical settings, to examine our current prac-
tice models to ensure that the Veterans we serve are pro-
vided excellent treatment at each point that they access 
our systems of care. Improving awareness and under-
standing of these two conditions and their intersection 
only helps to enhance provider satisfaction and improve 
clinical outcomes for patients.
The recommendations based on consensus of a work-
ing group of clinical experts for the PTSD clinical practice 
guideline include a series of 10 recommendations for the 
management of PTSD and chronic pain. Each is briefly 
outlined and discussed.
Recommendation 1
The first recommendation suggests obtaining a pain 
assessment using a 0 to 10 numerical pain rating scale, 
with 10 being the worst pain ever experienced. Pain 
scores 4 are considered to require clinical attention and 
further examination. This is a subjective scale and takes 
the score reported by the patient at face value based on 
self-report of their pain experience. The pain assessment 
is reassessed throughout clinical care and allows changes 
to the individual’s treatment plan to be made through col-
laboration based on the reported outcome.
Recommendation 2
A thorough biopsychosocial history and assessment 
for other medical and psychiatric illnesses is the second 760
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recommendation. Important components of the assess-
ment process include a comprehensive suicide and homi-
cide risk assessment. Specific questions about alcohol and 
substance use, such as over-the-counter medication; caf-
feine; herbal remedies; and prescription drugs, including 
controlled substances such as narcotic pain medications 
and benzodiazepines, is also important to the develop-
ment of a comprehensive and safe individualized plan of 
care that also takes patient preferences into consideration.
Recommendation 3
The third recommendation includes a comprehensive 
assessment of the nature of the pain and determines the 
likely etiology, such as musculoskeletal and/or neuro-
pathic pain, along with identifying the locations, quality, 
quantity, triggers, intensity, and duration of the pain and 
the potentially aggravating and relieving factors.
Recommendation 4
The fourth recommendation includes an evaluation of 
the effect of pain on function and activities, including 
pain-related disability or interference of pain with daily 
activities. Some individuals may report pain at a relatively 
high level; however, their overall functional impairment 
may not be evident because they may have learned to live 
with their pain and have found adaptive ways to cope with 
their pain. In these scenarios, pain does not adversely 
affect their overall quality of life. It is important to not 
only obtain a total pain score but also to relate this pain 
score to the overall reports of functional ability and life 
quality.
Recommendation 5
The fifth recommendation includes an assessment that 
identifies the avoidance behaviors that contribute to emo-
tional distress and/or impairment in functioning. These 
pain-related avoidance behaviors may include reduced 
activity caused by pain that is exacerbated with daily activi-
ties, thereby leading to deconditioning, further reduction in 
activity, and increased difficulty reengaging in previously 
enjoyed activities because of pain-related fears. These 
avoidance behaviors can also include the avoidance of cer-
tain places and situations that may trigger traumatic 
thoughts and images, such as being in crowded places or 
on busy highways or jogging in a woody or marshy envi-
ronment that is similar to previous combat experiences. 
Many individuals with PTSD and chronic pain will report 
avoidance of many previously enjoyed activities and the 
associated negative toll on their life, their self-confidence, 
and their relationships with their loved ones.
Recommendation 6
Management of pain should be multidisciplinary as 
part of the sixth recommendation. This should address the 
physical, social, psychological, and spiritual components 
of pain in an individualized treatment plan that is specifi-
cally tailored to the patient and type of pain. A team of 
clinical providers with varying expertise and clinical focus 
can be extremely helpful to the development of a compre-
hensive plan of care that can be implemented through the 
mechanisms that are available within multidisciplinary 
care teams. As previously mentioned, an important com-
ponent of this multidisciplinary approach is to take into 
consideration patient preferences and to have a number of 
different treatment options available that will fit best with 
the individual patient and his or her goals for recovery.
Selection of treatment options should also balance 
the benefits of pain relief with possible adverse effects on 
the individual’s ability to participate in and benefit from 
PTSD treatment. Narcotic pain medications have a num-
ber of side effects, including, but not limited to, sedation, 
cognitive impairment, weight gain, constipation, and 
exacerbation of comorbid sleep difficulties such as sleep 
apnea. Cognitive impairment, sleep difficulty, and seda-
tion are the primary adverse effects that may interfere 
with an individual’s ability to fully engage in and benefit 
from the evidenced-based treatments for PTSD, including 
cognitive processing therapy (CPT) and prolonged expo-
sure (PE) therapy.
Recommendation 7
The seventh recommendation focuses on balancing 
the risks of pain control with the overall benefits. Often, 
patients will present for treatment in a PTSD clinical care 
area with reports of excessive fatigue, difficulty sleeping, 
sexual dysfunction, and memory trouble. It can be quickly 
assumed that the symptoms of PTSD can drive some of 
these reported complaints and the reflex action may be to 
increase sleep medications or adjust antidepressant agents 
to address what could be considered symptoms of depres-
sion or PTSD. Stepping back and inquiring into pain medi-
cation use and how the medications are taken by the
individual with PTSD can be very helpful. It is not 
uncommon to hear from patients that they may take extra 
doses of their pain medications at night to help improve 
sleep for fear of going to sleep because of nightmares. 761
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Clinicians may also hear that patients are not taking their 
pain medications as prescribed for fear of running out of 
the medications and then the fear of going into narcotic 
withdrawal if they do not receive their new prescription 
on time. Some patients with both PTSD and chronic pain 
will also report taking as-needed narcotic pain medica-
tions to treat re-experiencing symptoms of PTSD.
Although psychiatrists and mental health providers may 
not prescribe narcotic pain medications, there is a unique 
opportunity, through the development of trust and rapport, 
for mental health providers to be able to provide feedback 
to patients about how they can safely take their medica-
tions and attend to the current presenting symptoms. Psy-
chiatrists should also be able to look at the presenting 
symptoms and/or complaints and make changes to the 
treatment plan should patients report taking their narcotic 
pain medications other than as prescribed. Those who pre-
scribe pain medications to patients with PTSD and 
chronic pain will appreciate the collaboration from psy-
chiatry and the patients will benefit from the combined 
attention to their recovery.
Recommendation 8
The eighth recommendation approaches the treatment 
of musculoskeletal pain syndromes with correction of the 
underlying condition and treatment with nonsteroidal
anti-inflammatory drugs (NSAIDs). Rush et al. stated that 
treatment with some NSAIDs may prevent the antidepres-
sant action of selective serotonin reuptake inhibitors 
(SSRIs) [63]. These studies showed that SSRI antidepres-
sants increase brain levels of cytokines and a small pro-
tein known as p11, the effect of which is abolished by 
NSAID cotreatment. NSAIDs antagonize both biochemi-
cal and behavioral responses to SSRIs for the treatment of 
depression. The effect on the use of NSAIDs for musculo-
skeletal pain in patients receiving treatment for PTSD 
with SSRIs has not been researched. Rush et al. believe 
that reduced use of NSAIDs by physicians in severely 
depressed patients being treated with SSRIs would signifi-
cantly improve positive outcomes from this major class of 
antidepressants [63]. Clinicians should balance the thera-
peutic benefits of NSAIDs with the potentially negative 
consequences of antagonizing the efficacy of antidepres-
sants in patients with depression [63].
Recommendation 9
When clinically appropriate, the ninth recommenda-
tion includes the use of nonpharmacological modalities 
for pain control, such as massage; BF; physical therapy; 
and complementary and alternative medicine (CAM) 
modalities such as yoga, meditation, and acupuncture. To 
manage both PTSD and chronic pain, it is crucial to 
develop an individualized treatment plan with patient 
involvement in all aspects of the care plan. It is important 
to be where the patient is at in his or her care plan 
because recommendations that we may propose based on 
the evidence and clinical research may not match the 
desired plan of care that our patients would like to follow. 
Having options available to improve quality of life for 
those patients who prefer CAM modalities for the man-
agement of pain will only help to improve and solidify 
the therapeutic relationship with the hopes that this will 
lead to improved outcomes for the patient. Perhaps this 
can also be viewed as an initial step in tackling the dis-
abling avoidance that paralyzes so many patients with 
PTSD and chronic pain. If our patients are able to achieve 
small successes, regaining their confidence and strength-
ening their self-esteem, we may be able to help them take 
the next step to engage in the evidenced-based psycho-
therapies for PTSD.
Some clinically relevant pain coping strategies
include activities that increase patients’ abilities to man-
age their symptoms and improve their daily functioning. 
Clinicians may recommend activities such as physical 
exercise, social interactions, and recreational activities. 
Hyperarousal in the setting of PTSD and chronic pain 
can be quite disabling; therefore, employing relaxation 
therapy can be an effective and important coping strategy 
for the self-management of both of these conditions [64]. 
Clinicians should be able to provide education and train-
ing in relaxation methods such as diaphragmatic breath-
ing, progressive muscle relaxation, and autogenics. These 
positive coping techniques have the ability to serve a dual 
purpose for a specific subset of patients who are willing 
and ready to engage in CAM modalities. These modali-
ties have been shown to help patients cope with chronic 
pain and can also help individuals cope with the disabling 
symptoms of PTSD.
Recommendation 10
The tenth recommendation advises caution in the use 
of centrally acting medications for the treatment of chronic 
pain in patients with PTSD because these medications may 
cause confusion and deterioration of cognitive perfor-
mance, thereby potentially interfering with the recovery 
process. The 2010 VA/DOD clinical practice guideline for 762
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managing opioid therapy for chronic pain advises the use 
of opioids for patients with moderate to moderately severe 
pain after measuring whether the benefits of opioid therapy 
are likely to outweigh the risks. In prescribing opioids, it is 
crucial that the patient is fully informed and consents to 
therapy and that very clear and measurable treatment goals 
are established. Centrally acting agents must provide effec-
tive pain relief with the best benefit-to-harm profile for the 
individual patient [65]. If pain relief is not provided with 
narcotic pain medications, then the plan of action and 
approach should be modified.
This is a very important recommendation given that 
many Veterans receive treatment for their chronic pain 
problems within primary care settings, and often, primary 
care providers may not have ready access to the expertise 
of pain specialists and mental health clinicians. It is not 
uncommon to hear from very busy primary care provid-
ers that they have a duty and moral obligation to treat a 
patient’s chronic pain when the pain score exceeds 4. 
That is absolutely the case because this pain score 
requires clinical attention and further examination. How-
ever, for many of these clinicians, their recommended 
treatment often results in providing a prescription for an 
opiate pain medication given their time constraints and 
their ethical obligations to address pain in their patients 
who are suffering. The importance of the biopsychosocial 
evaluation must be stressed in this setting so that the 
patient’s pain experience is fully defined prior to recom-
mending treatment options. The best treatment is not 
likely to be a prescription for an opiate pain medication 
for patients with both PTSD and chronic pain. Integrated 
care models will prove to be of incredible assistance to 
all of our primary care providers because these clinicians 
also individually struggle to manage the complexities of 
both PTSD and chronic pain.
SPECIAL FOCUS ON CENTRALLY ACTING PAIN 
MEDICATIONS IN PTSD AND CHRONIC PAIN
When examining prescription pain medication use in 
patients who have PTSD and chronic pain, we can clinically 
see how this can pose challenges to both the patient and the 
provider. As mental health providers, we often see opiates 
being misused by our patients in order to manage emotional 
distress and avoid combat-related intrusive thoughts and 
memories. Seeing this happen with patients who have 
PTSD can be quite challenging to primary care and mental 
health clinicians, along with the patient’s family members. 
It can be helpful to understand the path that may lead to the 
initiation of a prescription pain medication and the process 
that should be in place to identify problems with patients 
sooner rather than later. The importance of interdisciplinary 
care and communication cannot be stressed enough in these 
particular cases.
For the most part, psychiatrists will not be the pre-
scribers of narcotic pain medications; however, gaining an 
understanding of the process and screening in place to pre-
scribe pain medication is quite relevant to the mental 
health treatments we provide. Before a narcotic pain medi-
cation is prescribed, a comprehensive assessment that 
includes a complete history and physical examination with 
clinically indicated diagnostic studies should be con-
ducted. Completing a risk assessment for aberrant drug-
related behaviors and using risk stratification instruments 
such as the Opioid Risk Tool and Screener and Opioid 
Assessment of Patients with Pain (version 1 and revised) 
can prove to be very beneficial [66–68]. Clinicians who 
are providing mental health care to patients with PTSD and 
chronic pain will likely not be the providers prescribing 
pain medications; however, they are in a unique position 
given the development of trust and therapeutic rapport that 
is the foundation of the treatment of PTSD. Mental health 
providers have the opportunity to work alongside the clini-
cians who are prescribing pain medications to offer valu-
able input to the prescribers and to the patients. Inquiring 
into opiate use can provide a wealth of information on the 
Veteran’s current status in regards to both chronic pain and 
PTSD, along with his or her overall quality of life and 
functional ability. This is also an opportunity to assess a 
patient and determine whether or not there is a problem 
with addiction to pain medications since this will require a 
change in plan of care that should most definitely be coor-
dinated with the prescribing provider.
Some questions that can be asked during the mental 
health evaluation and treatment process include—
  • How often do you take more pain medication than you 
are supposed to?
  • When was the last time you took additional doses of 
pain medications so that you could fall asleep at 
night?
  • How often have your pain medications been lost or 
stolen?
  • How often has more than one doctor prescribed pain 
medication for you at the same time?
  • How often do you run out of your pain medications?763
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  • Do you call for early refills or do you wait for your 
next scheduled appointment?
These questions and the answers provided by the patient 
can offer valuable information into the patient’s recovery. 
It is common to hear from patients with PTSD and chronic 
pain that they frequently run out of their narcotic pain 
medications, feel ashamed, and do not call their prescrib-
ing provider. These patients routinely experience the 
uncomfortable effects of opiate withdrawal, including
diarrhea, muscle aches, abdominal cramping, nausea, and 
increased anxiety and agitation, which often exacerbate 
PTSD symptoms. Again, another reflex action may be to 
increase the dose of sertraline to address the surface PTSD 
symptoms, when in fact, the patient could benefit from 
some ibuprofen or perhaps clonidine, loperamide, and/or 
Bentyl to target what are actually opiate withdrawal symp-
toms. Posing some of the above questions will also let the 
mental health provider know how severe and intense the 
patient’s PTSD symptoms are at the present time. If 
patients report taking too much pain medication and then 
running out, it can alternatively be helpful to consider 
increasing their SSRI and/or referring the patient for fur-
ther psychotherapeutic intervention to manage their PTSD 
symptoms before the patient attempts self-management of 
their PTSD symptoms with narcotic pain medications. 
Working with the patient who has PTSD and chronic pain 
and pointing out the cycle of avoidance can help some 
patients engage in the necessary trauma therapy services. 
In essence, patients may be managing their PTSD symp-
toms through self-medication, by avoiding their feelings 
and numbing their intolerable emotions with narcotic pain 
medications and then, unfortunately, leading themselves 
down a dangerous path of self-destruction.
There is a complex interaction between the person at 
risk and properties of certain drugs, such as the long- versus 
short-acting narcotic pain medications. Drug properties and 
prescribing patterns for pain medications should be taken 
into consideration when working with patients who have 
PTSD and chronic pain. Short-acting pain medications have 
a more rapid onset and offset of action, with an increased 
propensity for the development of addiction than long-
acting agents. Selecting pain medications with a longer 
half-life can help to possibly curb addiction potential and 
medication misuse.
There are also opportunities for intervention in refer-
ence to provider prescribing patterns based on clinical 
observations in patients with both PTSD and chronic pain. 
Prescriptions written for as-needed dosing can sometimes 
cause confusion for some patients with PTSD. Patients 
have reported that they will hold off on taking their medi-
cations so that they can have additional doses available 
should they have problems with re-experiencing symp-
toms, such as nightmares or intrusive thoughts. Some 
patients have even reported taking their pain medications 
following disagreements or arguments with their family 
members as a strategy to manage their anger and irritabil-
ity. Scheduled doses of pain medications at specific times 
of the day can help to modify the risk of confusing chronic 
pain symptoms with normal emotional or psychiatric 
symptoms for patients with both PTSD and chronic pain. 
Questions about how patients take their pain medications 
can provide very fruitful information for mental health 
providers because they can learn more about the specific 
symptoms of both PTSD and chronic pain for patients 
throughout the day and how they may attempt to self-
manage their own psychological and physical distress.
Knowledge of the nonmodifiable risk factors for 
addiction, such as a family or personal history of sub-
stance abuse or addiction, a personal psychiatric history 
of any kind, age (younger age carries a greater risk poten-
tial), current status as a smoker, and a personal history of 
preadolescent sexual abuse, can yield helpful information 
in the care of patients with both PTSD and chronic pain.
If a mental health provider working with a Veteran who 
has PTSD and chronic pain has an understanding of the 
specific aberrant medication-related behaviors, this knowl-
edge will only help to integrate and coordinate care with 
the primary care providers. Some of these specific aberrant 
behaviors include, but are not limited to [69]—
  • Requests for higher medication doses without improve-
ment in pain status with dose escalation.
  • Early refills.
  • Extra medication requests because of frequent travel 
or inability to attend more frequent visits.
  • Lost medications.
  • Multiple unsanctioned dose escalations.
  • Unexpected urine toxicology results showing absence 
of opiates or presence of illicit substances.
  • Deterioration in occupational, family, or social
functioning.
  • Resistance to changing or tapering opiates, despite a 
number of adverse effects to the medications.
  • Refusal to comply with urine drug screens as needed 
during treatment.
  • Concurrent abuse of alcohol or illicit substances.764
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  • Use of multiple physicians and pharmacies.
Evidence of the above aberrant behaviors for a patient 
who is prescribed opiates requires further discussion and 
assessment of substance dependence while coordinating 
this plan of care with the prescriber of the pain medica-
tions. The clinical expertise of substance abuse special-
ists can be helpful in these types of situations.
With the use of narcotic pain medications, ultimately 
the goal of treatment is to provide sustained analgesia and 
improvements in sleep and quality of life. It is crucial to 
carefully screen patients being considered for long-term 
opiate therapy and be able to identify patients who may 
have difficulties with managing opiates. Even if the men-
tal health provider may not be the prescriber of pain medi-
cation, awareness of these risk factors when patients who 
present in different settings, such as mental health, and 
report a variety of symptoms that may or may not be side 
effects of narcotic pain medications can only help to pro-
vide high quality of service to Veterans. Awareness of 
these risk factors and the presenting characteristics of 
addiction can be especially helpful in developing the best 
plan of care for patients with both PTSD and chronic pain.
Importantly, patients with both PTSD and chronic pain 
should not be denied access to opiate therapy; however, 
they may require more focused monitoring with increased 
frequency and intensity of visits with urine drug screens to 
confirm the presence of the prescribed medication and to 
confirm the absence of illicit substances given the 
increased risk for development of a substance use disorder. 
With the prescription of any medication for patients, 
whether it is a narcotic pain medication for chronic pain or 
an SSRI for the treatment of PTSD, the medication treat-
ment must provide the following:
  1. Analgesia and/or modification of PTSD symptoms.
  2. Improvements in activities of daily living with reduc-
tion in avoidance behaviors.
  3. Careful monitoring of adverse effects, such as seda-
tion, cognitive impairment, constipation, sexual dys-
function, and then an adjustment in plan of care as 
indicated.
  4. Monitoring for aberrant drug-related behaviors, such as 
running out of medication, overusing medications, and 
seeking prescriptions from multiple providers [70].
Evidence of aberrant drug-related behaviors requires deci-
sive action, and in most cases, continued prescription of an 
opiate pain medication is not recommended given the 
inherent health risks, including accidental overdose. There 
is a greater rate of accidental poisoning deaths among Vet-
erans than nonveterans, and the risk of accidental poison-
ing death relative to the general population is larger than 
that of suicide. Opiate medications are frequently the sub-
stance responsible for accidental poisoning death in VHA 
patients. We must look closely at prescription pain medica-
tion use in our at-risk patients by conducting biopsychoso-
cial assessments and comprehensive risk assessments and 
examining strategies to prevent overdose in patients with 
PTSD and chronic pain [71].
PTSD, Chronic Pain, and Addiction
For Veterans with PTSD, chronic pain, and opiate
addiction, some viable options have been effective during 
clinical work with this patient population. Engagement 
through immediate or same-day substance abuse consulta-
tion is recommended. Motivational interviewing can help 
to address ambivalence about treatment. Following detec-
tion and assessment for opiate abuse or dependence, the 
option of combined buprenorphine and naloxone (Subox-
one) can be considered. Along with maintenance pharma-
cotherapy for opiate addiction, voucher- or monetary-based 
incentive programs, CBT, and relapse prevention are gener-
ally efficacious [72–73]. Acceptance and commitment 
therapy have also been found to be effective for pain man-
agement and substance abuse treatment [74–76].
Managing addiction with combined buprenorphine 
and naloxone offers opportunities for pain management 
based on the mechanism of action of the medication [77]. 
With agonism at the mu opioid receptor, moderate pain 
relief can be achieved. Antagonism at the kappa receptor 
functions to minimize hyperalgesia. This treatment may 
be inferior to higher-dosage opioids for pain relief 
because it is only a partial agonist at the mu receptor; 
however, by breaking the cycle of intoxication, with-
drawal, and functional impairment for those with opioid 
addiction, this treatment alone can help to achieve stabili-
zation of a potentially deadly addiction and can modify 
the physical and emotional distress of addiction that can 
exacerbate PTSD symptoms and chronic pain.
Pain relief from buprenorphine diminishes above 
doses of 4 mg and analgesia typically lasts 8 hours per 
dose. Effective pain relief and stabilization of opioid 
addiction for those with PTSD, chronic pain, and addiction 
have been found to occur at doses of 4 mg taken sublin-
gually three times per day. Additional pain management 
modalities are also recommended, including, but not limited
to, physical rehabilitation with exercise and stretching as 
tolerated, nonnarcotic medications to manage pain, BF, 765
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behavioral activation (BA), and acceptance and commit-
ment therapy. Chronic pain complicates management of 
opioid addiction and PTSD. Treatment collaboration fol-
lowing an integrated care model will help patients to 
achieve adequate pain relief and improvement in overall 
quality of life and functioning with successful stabilization 
of opiate addiction and the associated physical and emo-
tional difficulties.
For patients with PTSD and chronic pain, it is also 
important to differentiate between opioid use disorder and 
pseudoaddiction. The difference has clear treatment 
implications for pain management and substance abuse 
treatment. Pseudoaddiction is described as opioid-seeking 
behavior with requests for dose escalations caused by 
inadequately treated pain [78]. This similar pattern can 
also be seen in patients with inadequately treated depres-
sion and anxiety disorders such as PTSD [79]. This again 
triggers the need for a comprehensive biopsychosocial 
assessment and an integrated interdisciplinary care treat-
ment approach. Pseudoaddiction resolves with adequate 
relief of pain, at times not even with opioids as the treat-
ment option, and does not involve maladaptive patterns of 
substance abuse that can lead to clinically significant 
impairment. It can therefore be hypothesized that relief of 
anxiety and depressive disorders through evidence-based 
psychological and psychiatric treatment for PTSD can 
function to modify aberrant drug-related behaviors.
Pharmacological Management of PTSD and Chronic 
Pain
Pharmacological management of chronic pain in Veter-
ans with PTSD is one component of treatment; however, no 
studies evaluating pharmacotherapy and functioning for 
patients with comorbid pain and PTSD have been examined 
to date. Pharmacological management has typically been 
completed through side-by-side management with the most 
common first-line treatments for pain, including acetami-
nophen, NSAIDs, opioids, tramadol, anticonvulsants, tricy-
clic antidepressants (TCAs), and serotonin-norepinephrine 
reuptake inhibitors (SNRIs).
The first-line pharmacotherapy for PTSD includes 
SSRIs, with Food and Drug Administration (FDA) 
approval for the use of sertraline and paroxetine for the 
treatment of PTSD with limited support for their efficacy 
in the treatment of pain. Venlafaxine is also a first-line 
treatment for PTSD within the class of antidepressant 
agents referred to as SNRIs and is also effective in the 
management of some chronic pain syndromes.
Based on the current research available, the treatment 
and pharmacological management of PTSD and chronic 
pain have historically been off-label and driven by clini-
cian prescribing patterns with reported relief and modifi-
cation of PTSD and pain symptoms from treated patients.
MOST COMMON PAIN COMPLAINTS IN 
PATIENTS WITH PTSD
The three most common pain complaints reported to 
providers working in the PTSD clinical program in 
Tampa, Florida, are back pain, headaches, and neuro-
pathic pain. This article examines pharmacological man-
agement and therapeutic recommendations to modify the 
pain experience because pain can drive the constellation 
of PTSD symptoms for patients. For many of the patients 
treated in this clinic, their preference is to continue their 
medical and pain management treatment with the provid-
ers with whom they have developed and established trust 
and rapport. Often we may recommend referral to a pain 
management program but this is declined by many 
patients, citing that they are unfamiliar with the program 
and they believe that they are “too sick or completely 
broken” if they need to be referred to another clinical 
program. By attempting to alleviate suffering and provide 
some measure of comfort to patients, some treatments are 
initiated in the PTSD clinical program with the hope that 
this can help build a bridge to more intensive pain man-
agement services as clinically indicated.
Back Pain
Back pain is one of the leading causes of long-term 
disability in the United States today. Back pain can be 
triggered by a number of different injuring mechanisms, 
including direct injury to the vertebrae, facet joints, nerve 
roots and/or muscle and connective tissue damage. For 
many patients, there is no direct relationship between 
physical findings discovered on examination or diagnos-
tic testing and the patient’s perceived level of pain, dis-
ability, and psychological distress. If back pain is 
disproportionate to findings on examination, there tends 
to be a greater propensity toward the presence of an 
underlying depression and associated maladaptive cogni-
tive patterns, including catastrophic thinking.
When treatment options are examined upon identifica-
tion of the cause of the chronic back pain, recommenda-
tions include returning to activity as soon as possible to 766
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prevent the cycle of deconditioning and further difficulty 
returning to previous levels of activity. Starting with con-
servative management and then moving ahead is typically 
the best and most agreeable option for many patients. Exer-
cises that are recommended by primary care providers and 
rehabilitation specialists include flexibility, range of
motion, aerobic activities, and muscle strengthening exer-
cises. Medications include NSAIDs, acetaminophen, trama-
dol, and some antidepressant agents provided there is a
comorbid depression. Antidepressants with SNRI, such as 
venlafaxine and duloxetine, have proven to be viable 
options for the treatment of chronic back pain, whereas the 
SSRIs have not proven as effective for pain relief; however, 
sertraline, paroxetine, and venlafaxine are the only antide-
pressants considered first-line treatment of PTSD. Addi-
tional psychotherapeutic options include a course of CBT 
and teaching relaxation techniques, with some patients pre-
ferring CAM such as acupuncture, massage therapy, and/or 
yoga. Surgery and spinal cord stimulation are typically 
reserved for patients with minimal response to a range of 
the previously mentioned treatment options [80].
Headache
Headaches are the second most common report of 
ongoing pain and distress for patients in the Tampa PTSD 
clinical program. The most prevalent headaches are ten-
sion and migraine in origin. Tension headaches can be 
described as pressing and tightening, band-like, surround-
ing the head and bilateral in presentation. Some consider 
tension headaches a variant of migraine headaches and 
they are thought to arise from myofascial pain sensitivity 
and increased pericranial muscle activity. This can be 
brought on by both physical and psychological stress 
because emotional distress may contribute to muscle con-
traction driving the tension headache. These types of 
headaches are exacerbated by poor posture and other 
ergonomic factors, such as carrying loaded bags, com-
puter work, and heavy military equipment such as head-
gear. Dental complications may predispose some people 
to tension headaches and they may need occlusal adjust-
ments, splints, or masticatory exercises. Bruxism is com-
mon in PTSD and is also a side effect of SSRIs; this in 
itself can drive tension headaches. Abortive treatment 
strategies include NSAIDs, acetaminophen, and aspirin. 
Chronic tension headaches can respond to prophylactic 
agents such as TCAs, SSRIs, and SNRIs. Stress manage-
ment, BF, relaxation training, dental referral, and CBT are 
also helpful strategies for some patients.
Migraine is a chronic disabling neurologic pain syn-
drome that requires optimal pharmacological care to 
restore patients to normal functioning and to prevent sig-
nificant disability. PTSD is more common in chronic 
migraine than in episodic migraine. PTSD may be a risk 
factor for chronic headaches, with treatment of migraine 
headaches being complicated by the fact that patients 
react in different ways to medications. What may work 
for one patient may not work for another, especially in 
those with PTSD [81].
Acute migraine treatment involves the use of triptans 
or ergots. Triptans are serotonin agonists and caution must 
be used because of the risk of serotonin syndrome in 
patients with PTSD who are also taking SSRIs. Educating 
the patient about the signs and symptoms of serotonin syn-
drome is important to ensure safe management of migraine 
headaches. Patients should be instructed to take the triptan 
at the earliest onset of mild pain, before full-blown 
migraine, to maximize a sustained pain-free response. It is 
not uncommon for patients with PTSD to wait until they 
have a full-blown migraine episode before taking the trip-
tan. Many will report that they felt they could work 
through the headache on their own; therefore, they waited 
too long to abort the episode. It is important to use the 
agent less than 10 days per month to avoid transformation 
to chronic daily headache and to avoid rebound headaches. 
NSAIDs, small amounts of caffeine, and antiemetics for 
additional relief of associated nausea can also be pre-
scribed. Ergots (dihydroergotamine) come in injection and 
nasal spray formulations and are used in those who do not 
tolerate triptans; those who failed triptan therapy; or in 
those with prolonged, disabling episodes [82].
Daily preventive treatment for chronic migraine is typi-
cally recommended when the frequency or disability of 
migraine is high; when there is risk of neurologic injury 
(hemiplegic migraine); or when acute therapies are con-
traindicated, not tolerated, or overused. Preventive treat-
ment for migraines decreases hyperexcitability by reducing 
cortical spreading and neuronal activation. The overall effi-
cacy of prophylactic classes is similar and selection should 
be based on treating comorbid conditions.
Amitriptyline, propranolol, timolol, divalproex sodium, 
and topiramate are viable options for preventive treatment of 
migraines. The dual-action antidepressants have efficacy 
for migraine. For patients with PTSD, only venlafaxine is 
recommended as a first-line treatment. The SSRIs regarded 
as first-line treatments for PTSD have performed poorly 
for migraine prophylaxis. All of these medications, when 767
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used at appropriate doses for at least 2 to 3 months, yield 
approximately a 50 percent reduction in migraine frequency. 
Guidelines suggest starting with a low dose and treating to 
effect or the development of intolerable side effects. Other 
classes of medications, such as the calcium channel blockers 
(verapamil), SNRIs (venlafaxine), angiotensin-converting-
enzyme inhibitors (lisinopril), angiotensin receptor blockers 
(candesartan), clonidine, NSAIDs, or natural supplements 
(magnesium, riboflavin, coenzyme Q10), have less evidence 
for the treatment of migraine headaches. CBT should also 
be recommend for patients with PTSD and chronic migraine 
headaches to help the patient achieve desired recovery and 
relief [83].
For patients who have failed pharmacological treat-
ment modalities for the management of chronic migraines 
and for patients who prefer to not take oral medications, a 
referral to neurology for injection of onabotulinumtoxinA 
(BOTOX) as a headache prophylaxis in adults with 
chronic migraine can be a viable treatment option.
BOTOX injections have been shown to reduce headache-
related disability and improve functioning, vitality, and 
overall health-related quality of life [84].
Neuropathic Pain
Neuropathic pain is the third most common report of 
pain in patients who receive treatment in our PTSD clini-
cal program. Adequate treatment of neuropathic pain to 
reach desired pain relief for patients is difficult to achieve. 
The efficacy of drugs for neuropathic pain has been estab-
lished in randomized clinical trials (RCTs) that have 
excluded patients with comorbid conditions and those tak-
ing complex medications. Application of the evidence can 
become quite difficult for the treatment of Veterans with 
comorbid disorders including, but not limited to, PTSD 
and chronic pain.
Neuropathic pain is very frustrating for many 
patients and treating providers because inadequate pain 
relief may lead to complete disability. Often, to modify 
the pain experience, complex pharmacology regimens are 
recommended after examination of the cause of the pain; 
attempting to modify or control comorbid medical condi-
tions that can exacerbate neuropathic pain, such as poorly 
controlled diabetes; and examining additional factors to 
allow for development of an individualized plan of care.
For many of the patients in our PTSD clinical pro-
gram, the most common causes of neuropathic pain are 
diabetes, Agent Orange exposure, vitamin B12 deficien-
cies, thyroid disease, alcohol use, chemotherapies, entrap-
ment neuropathy (carpal tunnel, ulnar entrapment), and 
poststroke syndromes [85]. Aggressive action is taken to 
correct and control underlying medical conditions that can 
worsen neuropathic pain, such as repleting vitamin B12 
levels, addressing alcohol use disorders, and improving 
hemoglobin A1c control for patients with diabetes.
The frequent neuropathic complaints  include the 
following:
  • Allodynia: Pain produced by nonnoxious stimuli; try-
ing to go to sleep at night and experiencing intense 
pain upon placing the sheets on his/her feet.
  • Hyperalgesia: Exaggerated pain response to noxious 
stimuli; walking barefoot on a gravel road feels like 
walking on hot charcoal.
  • Dysaesthesia: Unpleasant sensation, not always pain-
ful; when patients have a difficult time describing 
their pain symptoms and may often say, “It just feels 
weird . . . not normal.”
  • Paraesthesia: Pins and needles that can be described 
as sharp, stabbing, shooting, tingling discomfort and 
pain; frequently described as distracting and unex-
pected and leading to a feeling of uncontrollability 
and emotional distress.
Veterans with PTSD and neuropathic pain can experience 
significant functional impairment, including pain that 
interferes with sleep, and develop problems with balance, 
tripping, and falls, especially upon awakening at night 
after nightmares and then pacing the floors in their home. 
Determining the specific causes of a patient’s sleep diffi-
culties, such as neuropathic pain and/or nightmares, and 
then being able to offer modalities to modify his or her 
pain and other PTSD symptoms can be extremely helpful. 
We have also found that it is helpful for patients with 
PTSD and neuropathy to create a safe environment prior 
to going to sleep to reduce the risk of accidental injury 
and falls should they wake up at night. The hallways 
should be clear and a path to the bathroom and stairwell 
should be free of all items such as books, newspapers, 
shoes, and toys. Additional lighting can also help reduce 
the possibility of tripping and injury.
TCAs, gabapentinoids (including gabapentin and pre-
gabalin), selective noradrenergic reuptake inhibitors (ven-
lafaxine and duloxetine), and topical lidocaine are the first-
line choices. Selecting an agent should also consider the 
patient’s comorbid medical conditions and stability of any 
underlying mental illness given the risks of lethal overdose 
associated with TCAs. Additional agents are added as 
needed and with careful consideration and examination of 768
JRRD, Volume 49, Number 5, 2012
potential drug-drug interactions. Second-line agents include 
opioid agonists such as methadone and tramadol, again 
with careful consideration of opioid use for patients with 
comorbid disorders and risk factors for addiction. Third-
line agents, FDA-approved for the treatment of neuropathic 
pain, include anticonvulsants such as carbamazepine,
lamotrigine, topiramate, phenytoin, and valproic acid and
in addition have been observed to have beneficial effect for 
the modification of emotional lability and irritability during 
clinical work with Veterans with both PTSD and chronic 
neuropathic pain. Additional third-line agents include anti-
depressants such as bupropion, citalopram, and paroxetine, 
along with topical agents such as capsaicinoid that inhibits 
the pain-eliciting substance P [86–88]. A thorough review 
of the patient’s current medication profile, medical condi-
tions, and potential adverse drug-related effects must be 
carefully considered and monitored before prescription of 
any of the above agents.
Alternative interventions for managing neuropathic 
pain include BF, hypnosis, relaxation techniques, tai chi 
with the ability to improve motor function and balance, 
acupuncture, and occupational therapy. Transcutaneous 
electrical nerve stimulation and sympathetic nerve blocks 
have also been used with some effect for patients with 
debilitating neuropathic pain.
DISCUSSION
The management of both PTSD and chronic pain has 
been challenging for both primary care providers and psy-
chiatrists. Bridging the gap between mental and physical 
health truly requires a multidisciplinary approach because 
of the higher rates of morbidity and premature mortality 
compared with the general population [89]. People with 
serious mental illness are more likely to engage in 
unhealthy lifestyle practices, such as lack of physical 
activity, poor nutrition and overeating, smoking and other 
substance abuse, irregular and inadequate sleep, and fail-
ure to visit healthcare providers on a regular basis. Many 
of these unhealthy lifestyle practices, such as lack of exer-
cise, impaired sleep, obesity, and smoking, only drive and 
exacerbate chronic pain symptoms. Given the changes in 
our current healthcare systems, it has become judicious 
for both psychiatric and physical healthcare providers to 
broaden their treatment patterns to address the whole per-
son. An integral component of mental health services will 
be for psychiatric providers to make sure that the health 
status of all patients is assessed, that each individual has a 
primary care provider assigned, and that there is an effec-
tive mechanism in place for communication between the 
mental health and medical care providers. There is a 
growing need for a coordinated, multidisciplinary, holis-
tic approach to bridge the gap between physical and men-
tal health among patients with major psychiatric disorders 
and medical conditions such as PTSD and chronic pain.
Significant challenges face psychiatrists regarding 
the care of patients with mental illness and comorbid 
medical conditions. Both action and inaction in the case 
of medical illness for a patient who is treated in mental 
health can confer legal risks and liability. Psychiatrists 
have the greatest level of responsibility for medical con-
ditions that may be the result of an action taken by the 
psychiatrist, such as the development of diabetes in a 
patient who is receiving antipsychotic medications [90]. 
The psychiatrist is therefore obligated to be aware of the 
medical risks of psychiatric medications and to assist 
with appropriate monitoring and, if necessary, implement 
corrective actions on behalf of the patient [91].
Psychiatrists are likewise responsible for being aware 
of medical illnesses or treatments that can exacerbate the 
psychiatric illness that they are treating, and they have a 
duty to ensure that these medical conditions are properly 
addressed. In the case of patients with PTSD and chronic 
pain, understanding the effect of centrally acting pain 
medications on the body and emotions is essential to the 
care of patients with comorbid illnesses. This awareness 
will assist in the development of a sound and holistic 
individualized treatment plan that will also allow for 
coordination with the primary medical providers. With 
the extensive electronic medical records within the VHA, 
this coordination of care may involve a brief note in the 
medical record that requests an electronic signature or 
acknowledgment of receipt by other medical providers 
involved in the patient’s care. Alerting all providers 
responsible for the patient’s care, either through a tele-
phone call or electronic signature, allows for monitoring 
of the patient’s status and ensuring follow-through to 
address the medical condition of concern that requires 
clinical attention.
An integrated health clinic for chronic pain, stress-
related depression, anxiety, and PTSD in Salt Lake City, 
Utah, was designed for the nonpharmacological biopsy-
chosocial management of chronic pain and PTSD using 
CAM and mind-body skills also focused on lifestyle con-
cerns that affect health, such as obesity and tobacco use 769
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[92]. This program offers psychological, social, spiritual, 
and physical healthcare using CAM therapies. Acupunc-
ture, aquatic bodywork, stress management, hypnosis, 
meditation, qi gong, yoga, herb-drug interaction counsel-
ing, multidisciplinary weight management, and tobacco 
cessation classes were the foundation of therapies and 
classes offered. Each therapy and class correlates to a 
common philosophy of calm mind, thought and body 
awareness, use of pain and stress-management techniques, 
and promoting self-efficacy to enhance coping and well-
ness behaviors. This integrative care clinic and program 
offers an effective reduction in pain-related psychopa-
thology, depression, and anxiety and improved quality of 
life for up to 6 months or more upon completion of treat-
ment. This study was not designed to evaluate the effec-
tiveness of the individual therapies but was developed to 
determine the benefit of the program as a whole. Patients 
were empowered to use self-management tools to modify 
their pain and emotional distress. An RCT is needed to 
infer cause and effect or assess overall treatment effective-
ness. Selection bias was also a factor, such as belief in a 
new treatment, because many of the patients had chronic 
PTSD and depression for extended periods of time. How-
ever, it is important to acknowledge the use of CAM thera-
pies and their integration into conventional medicine
because many patients request access to these therapy 
options. This is an innovative treatment approach and fur-
ther research can prove to be beneficial to patients with 
comorbid illnesses such as PTSD and chronic pain.
One of the most efficient and efficacious treatments 
for PTSD is PE therapy, which involves repeated imagi-
nary exposure to the traumatic memory and repeated in 
vivo exposure to safe situations that were previously 
avoided [93]. CPT has also been found to be an effective 
treatment for PTSD across trauma populations and has 
also been successfully adapted for use with Veterans with 
combat-related PTSD [94]. Because Veterans access our 
VA medical systems from multiple points of care, it has 
become essential for our healthcare systems to adapt to 
the changing needs of patients. Given the increasing 
number of male and female Veterans entering into the VA 
system of care and the comorbid illnesses such as PTSD 
and chronic pain, integrated care models have begun to 
flourish.
Integrated care models have become an important 
part of mental health care, with many Veterans first being 
screened and diagnosed with PTSD in primary care clin-
ics. Unfortunately, the number of Veterans receiving an 
adequate treatment protocol for PTSD in mental health is 
few because of stigma and individual concerns such as 
travel, time, employment, and other competing priorities 
that interfere with full engagement in a course of evi-
denced-based treatment for PTSD [95–98].
Wagner et al. presented pilot data on a small random-
ized effectiveness trial that used an adaptation of BA for 
the early intervention of PTSD and depression among 
physically injured survivors of traumatic injury [99]. By 
blocking avoidance, BA is similar to in vivo exposure 
that is a component of PE therapy for PTSD and can be a 
useful technique for treating PTSD symptoms. BA differs 
from in vivo exposure in that BA keys in on activities 
that are reinforcing and consistent with the patient’s goals 
as opposed to those activities that are avoided because of 
fear or anxiety. Because of the new restrictions faced by 
many of the seriously injured participants, more time was 
spent on goal setting. Attention was also given to the 
range of avoidance factors, such as fear, pain, physical 
limitations, shame, and maladaptive cognitions, along 
with substance abuse if conceptualized as an avoidance 
behavior.
Through activity charting and scheduling, partici-
pants were able to see the relationship between avoidance 
and/or inactivity and fear and/or depression. For some, 
avoidance was maintained by a fear of what others would 
think of them with their injuries and fear of possible rein-
jury. Behavioral assignments progressed from activities 
that could be done from bed (such as watching movies, 
reading, or using the telephone), to those from a chair 
(computer activities) to those that required increased 
mobility (such as walking downstairs, walking around 
the block, or running errands). The graded assignments 
allowed for initial success and then the ability to continue 
to push forward to more challenging activities to eventu-
ally meet the patient’s desired goals.
This study showed that increases in guided activity 
can break the patterns of avoidance that function to main-
tain PTSD. Patients engaged in BA showed improvement 
in PTSD symptom severity and improvement in physical 
functioning posttreatment. The BA group did not demon-
strate significant improvements in depression, and this 
was felt to be related to the limited number of sessions 
(average 5.75) and that treatment outcome studies for 
depression provided up to 20 sessions of therapy [100]. 
Posttreatment PTSD scores remained elevated despite the 
effect of BA on PTSD severity. It is proposed that high 
levels of previous and recurrent traumatic life events 770
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attenuate response to treatment intervention [101]. It is 
possible that more than six sessions could be required for 
complete remission of PTSD symptoms among the seri-
ously injured patient population. Zatzick et al. proposed 
that the focus on increasing meaningful activity based on 
individual goal setting may be helpful for injured trauma 
survivors who face a number of new life obstacles [101]. 
Small successes can have much greater payoffs as indi-
viduals progress in treatment. Given the traditional mas-
culine stereotypes of combat Veterans, BA may also be 
effective for military populations who may struggle with 
stigma by allowing them to access their emotions for 
trauma processing therapy.
In 2010, BA as a treatment for PTSD and depression 
[102] was implemented as a primary care-based treat-
ment following the protocol developed by Wagner et al. 
[99] with more focus on PTSD and depression. The initial 
idea was to be able to offer an effective treatment in pri-
mary care that would allow more patient engagement, 
thereby maintaining fidelity to treatment and improving 
clinical outcomes. The results revealed significant and 
meaningful reductions in PTSD symptoms found on 
structured clinical assessments and self-report measures. 
PTSD treatment gains were maintained at 3-month fol-
low-up. There were meaningful improvements on depres-
sion and quality of life measures and Veterans reported a 
high satisfaction with treatment.
Following the work completed by Wagner et al. [99] 
that examined BA as an early intervention for PTSD and 
depression among physically injured trauma survivors, 
an integrated treatment approach for Veterans with 
comorbid PTSD and pain was initiated as a pilot study 
[103]. Using components of CPT for PTSD and CBT for 
chronic pain management, Otis et al. developed a 12-
session integrated treatment for PTSD and chronic pain 
[103]. Weekly readings and assignments were used and 
participants received pre- and posttreatment evaluations 
using measures of pain, PTSD, physical disability, and 
psychological distress.
There were a limited number of participants in this 
study, with only three completing the pilot study; however, 
an RCT is currently being implemented to examine the 
integrated treatment versus stand-alone treatments for 
PTSD and pain, such as CBT for pain, CPT for PTSD, and 
wait list control versus the integrated care model. There 
were many challenges faced during the pilot program, 
which included issues related to difficulty establishing trust, 
problems with treatment attendance, avoidance, and diffi-
culty completing the homework assignments. There was 
evidence of reduction in PTSD symptoms and improve-
ments in symptoms of chronic pain for some participants. If 
future RCTs reveal that the positive effects of integrated 
care are greater than the effects observed in patients who 
receive treatment for either PTSD or chronic pain alone, 
then this approach could have direct benefits on access to 
care and improvements in care for Veterans with comorbid 
PTSD and chronic pain.
CONCLUSIONS
The effect of OIF/OEF on the physical and emotional 
health of returning servicemembers has been personally 
witnessed by their loved ones and the medical providers 
who care for these former servicemembers. We are all 
constantly challenged to come up with new and innova-
tive ways to help Veterans strengthen their resilience, 
enhance their recovery, and promote their reintegration. 
We have learned a lot from all generations of war Veter-
ans over the years and we have become versed in the con-
siderable burdens that PTSD and chronic pain, along with 
other comorbid medical conditions, place on Veterans 
who have sacrificed for the service of our country. It is 
well known that untreated PTSD is specifically related to 
chronic physical and other mental health problems and 
that without treatment, the individual and his or her loved 
ones will unnecessarily struggle and suffer.
Integration of medical and mental health care, at all 
points that Veterans access VA healthcare services, will 
provide Veterans with the gateway to achieving life satis-
faction and healing from both PTSD and chronic pain. 
Independent of the combat theater in which a Veteran has 
served, it is crucial that clinicians and researchers 
develop more integrated treatment programs and strate-
gies to meet the needs of Veterans with PTSD and 
chronic pain. Pharmaceutical RCTs focused on these 
comorbid conditions are a must, along with further 
refinement of the integrated psychotherapeutic tech-
niques currently in the literature.
All Veterans who have honorably served our country 
have earned and truly deserve the most comprehensive, 
individualized, and holistic treatment approaches that can 
be made available. We are all challenged to increase our 
knowledge and expertise in these clinical areas as Veter-
ans access care through a variety of different clinical set-
tings. We should be able to meet them at each point of 771
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care through which they seek assistance. Veterans were 
members of some of the highest performing military com-
bat teams and they were asked to do the unimaginable and 
unthinkable under a considerable degree of physical and 
emotional distress. They accomplished their goals and 
they did this together. There is a lot that we can learn from 
Veterans, and we must work together to create and continue 
to develop these high-performing, integrated clinical treat-
ment teams to serve Veterans. We must share our clinical 
expertise and join forces to provide care where patients feel 
comfortable and where providers are not limited by disci-
pline or treatment setting. Leading-edge ideas and the dedi-
cation, commitment, and compassion of the medical
providers and researchers will pave the way. This has to 
happen as a team, as soon as possible, and with the Veteran 
and his or her family at the forefront.
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